Lawful Use Of Cannabidiols In Supplements ‘Different Than The Rest’ Of US FDA Regulations?
Executive Summary
CFSAN regulatory affairs chief Douglas Stearn says a regulatory pathway wouldn’t be an open door for CBD-containing food and supplements due to concerns about the ingredients’ safety. Legislation from Congress might "do something with CBD that’s different than the rest of the Food, Drug and Cosmetic Act," he says.
You may also be interested in...
Measuring Consumer Exposure Confounds US FDA’s Evaluation Of Cannabinoid Safety In Supplements
Acting commissioner Woodcock reminds manufacturers and marketers that a consumer’s exposure to cannabidiol and other cannabinoids likely comes from using multiple products daily. “How do you control exposure of people in a nonprescription setting?”
Legislating Hemp As Dietary Ingredient: Wrapping US Market In A Bow, Or Tying DSHEA In Knots?
House legislation to exempt hemp-derived cannabinoids from FDA rule that an “article” previously studied or approved for use as drugs is not allowed for use in dietary supplements either resolves a conundrum or raises additional questions for the agency and the industry.
UN Rejects Proposal To Exempt CBD From International Narcotics Controls
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.